Literature DB >> 12866939

Influence of solvents on the variety of crystalline forms of erythromycin.

Sabiruddin Mirza1, Inna Miroshnyk, Jyrki Heinämäki, Leena Christiansen, Milja Karjalainen, Jouko Yliruusi.   

Abstract

The influence of the organic solvents widely used in the pharmaceutical industry (acetone, methylethylketone, ethanol, and isopropanol) both in the presence and in the absence of water on the crystallization behavior of erythromycin (Em), a clinically relevant antibiotic of the macrolide group, was investigated. It was observed that despite a high preference for water as a guest molecule, Em rather easily forms solvates with the organic solvents studied. Consequently, 4 distinct solvates of Em have been isolated by recrystallization: acetonate, methylethylketonate, ethanolate, and isopropanolate. It was established that in a pure organic solvent, or 1:9 or 1:1 water-organic solvent mixtures, the corresponding solvate is always crystallized. However, the recrystallization of erythromycin from 2:1 water-organic solvent (excluding methylethylketone) mixture results in the formation of a crystal hydrate form. X-ray powder diffraction revealed the isostructurality of the solvates with acetone and methylethylketone. Thermogravimetric analysis showed that the loss of volatiles by all of the solvated crystals is nonstoichiometric. The desolvation behavior of the solvates with the organic solvents studied by means of variable-temperature x-ray powder diffraction indicates that in contrast to erythromycin dihydrate, they belong to a different class of solvates--those that produce an amorphous material upon desolvation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866939      PMCID: PMC2751520          DOI: 10.1208/ps050212

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  6 in total

1.  Assessment of amorphous content by microcalorimetry.

Authors:  Kohsaku Kawakami; Tetsuya Numa; Yasuo Ida
Journal:  J Pharm Sci       Date:  2002-02       Impact factor: 3.534

2.  Formation of isomorphic desolvates: creating a molecular vacuum.

Authors:  G A Stephenson; E G Groleau; R L Kleemann; W Xu; D R Rigsbee
Journal:  J Pharm Sci       Date:  1998-05       Impact factor: 3.534

3.  Alternate interpretation of the role of water in the erythromycin structure.

Authors:  J Baver; J Quick; R Oheim
Journal:  J Pharm Sci       Date:  1985-08       Impact factor: 3.534

4.  Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity.

Authors:  G A Stephenson; J G Stowell; P H Toma; R R Pfeiffer; S R Byrn
Journal:  J Pharm Sci       Date:  1997-11       Impact factor: 3.534

5.  Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation.

Authors:  J F Bauer; W Dziki; J E Quick
Journal:  J Pharm Sci       Date:  1999-11       Impact factor: 3.534

6.  Physico-chemical characterization of interactions between erythromycin and various film polymers.

Authors:  N Sarisuta; M Kumpugdee; B W Müller; S Puttipipatkhachorn
Journal:  Int J Pharm       Date:  1999-09-20       Impact factor: 5.875

  6 in total
  3 in total

1.  Crystal morphology engineering of pharmaceutical solids: tabletting performance enhancement.

Authors:  Sabiruddin Mirza; Inna Miroshnyk; Jyrki Heinämäki; Osmo Antikainen; Jukka Rantanen; Pia Vuorela; Heikki Vuorela; Jouko Yliruusi
Journal:  AAPS PharmSciTech       Date:  2009-01-30       Impact factor: 3.246

2.  Solubility Determination and Correlation of Warfarin Sodium 2‑Propanol Solvate in Pure, Binary, and Ternary Solvent Mixtures.

Authors:  Mery Vet George De la Rosa; Roberto Santiago; Joseph Malavé Romero; Jorge Duconge; Jean-Christophe Monbaliu; Vilmalí López-Mejías; Torsten Stelzer
Journal:  J Chem Eng Data       Date:  2019-04-01       Impact factor: 2.694

3.  Erythromycin A dimethyl sulfoxide disolvate 1.43-hydrate.

Authors:  Jürgen Brüning; Tanja K Trepte; Jan W Bats; Martin U Schmidt
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.